Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

Fig. 1

Elevated AHSA1 expression confers poor survival of MM patients and promotes MM cell proliferation. (A) HuProt™20 K Proteome Microarray Chip indicated the top 5 protein targets binding to Bufalin. The yellow arrow indicated positive protein interacted with Bufalin, and the blue arrow represented the negative control. (B) Among the top 5 proteins, AHSA1 was the exclusive gene. The signal level of AHSA1 was shown on the y-axis. Patients designated as healthy donors with normal bone marrow plasma cells (NP, n = 22), monoclonal gammopathy of undetermined significance (MGUS, n = 44) or multiple myeloma (MM, n = 351) were sorted on the x-axis. (C-D) Increased AHSA1 mRNA expression was positively associated with poor overall survival (OS) in first diagnosis and relapsed MM patients from (C) TT2 and (D) HOVON65 patient cohort. Events/N means events of death/total patients. (E) Representative Immunohistochemistry staining on primary MM samples (n = 15) and normal controls (n = 9). (F) Microscale thermophoresis (MST) analysis for the interaction of Bufalin with human AHSA1 recombination protein. (G) Validation of AHSA1 overexpression in AHSA1-OE ARP1 and H929 cells relative to control cells. (H) Cell cycle analysis for WT and AHSA1-OE cells. (I) Representative images of cell colonies of WT and AHSA1-OE cells in soft agar. (J) Confirmation of AHSA1 protein knockdown in ARP1 and H929 cells after transfection with AHSA1 shRNA. (K) Representative images of cell colonies of WT and AHSA1-KD cells in soft agar. (L) Cell cycle analysis for WT and AHSA1-KD cells. (M) WB analysis of PARP and Caspase 3. The data are expressed as mean ± SD.*p < 0.05, **p < 0.01, ***p < 0.001

Back to article page